Health Care & Life Sciences » Biotechnology | Voyager Therapeutics Inc.

Voyager Therapeutics Inc.

Voyager Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
32.44 M
Public Float
18.44 M
Voyager Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$2.94
Market Cap
$1.01 B
Shares Outstanding
36.83 M
Public Float
20.17 M

Profile

Address
75 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.voyagertherapeutics.com
Updated 07/08/2019
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A.

Financials

View All
Created with Highcharts 5.0.14Voyager Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.3 8333 83316 31716 31729 67229 67240 19340 19370 69870 69888 28888 288201320142015201620172018020k40k60k80k100k
Created with Highcharts 5.0.14Voyager Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.000017 33417 33414 22014 22010 13510 1357 6197 61920132014201520162017201805k10k15k20k

Mark Jay Levin
Chairman
G. Andre Turenne
President, Chief Executive Officer & Director